Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients

The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors is a feasible and effective treatment for patients with primary myelofibrosis.

Inclusion criteria

• Disease: Histologically proven Myelofibrosis with myeloid metaplasia/MMM defined as per the Italian Consensus Conference on MMM diagnosis with either primary MMM or secondary to Polycythaemia vera or essential thrombocythaemia with

• "intermediate risk" or "high risk" score according to the Lille Scoring System
• OR "low risk" score according to the Lille Scoring System with constitutional symptoms (fever, night sweat, weight loss > 5% of body weight)
• OR "high risk" score according to the Cervantes score
• Age:

• Patients between 50 and 70 years of age and no limited life expectancy for other reasons than MMM
• Patients under 50 years of age who are not eligible for a standard myeloablative conditioning, (e.g., because of prior autologous stem cell, history of severe infections like fungal infections, history of cardiac toxicity or other reasons according to the treating physician)
• HLA compatible or identical donor, related or unrelated (one mismatch allowed)
• Written informed consent of the patient

Exclusion criteria

• Positive search for bcr-abl on blood.
• Serious irreversible renal, hepatic, pulmonary or cardiac disease
• Central nervous involvement
• Positive serology for HIV
• Pregnant or lactating women
• Patients with a life-expectancy of less than six months because of another debilitating disease
• Serious psychiatric or psychological disorders